Program Schedule > Daily Schedule - Thursday, December 8, 2011
| |
|
Tuesday
|
Wednesday
|
Thursday
|
Friday
|
Saturday
|
| THURSDAY, DECEMBER 8, 2011 |
| |
|
|
| 7:00 am - 9:00 am |
POSTER SESSION 2 & CONTINENTAL BREAKFAST - Exhibit Halls A-B |
|
| |
|
|
| |
Tumor Cell Biology |
|
| |
Tumor Progression, Invasion, and Metastasis
Oncogenes/Tumor Suppressor Genes
Growth Factors
Apoptosis and Senescence
Angiogenesis
Genetics - Somatic Changes
Genetics - Germline Changes
|
P2-01
P2-02
P2-03
P2-04
P2-05
P2-06
P2-07 |
| |
Detection and Diagnosis - Imaging and Screening |
|
| |
Breast Imaging - MRI
Molecular, Functional, and Novel Imaging
Breast Imaging - Other Methods
|
P2-08
P2-09
P2-10 |
| |
Prognosis/Response Predictions |
|
| |
Prognostic Factors and Biomarkers - Preclinical
Prognostic Factors and Biomarkers - Clinical - 1
|
P2-11
P2-12 |
| |
Epidemiology, Risk, and Prevention |
|
| |
Familial Breast Cancer - Genetic Testing
Ethnic/Racial Aspects
|
P2-13
P2-14 |
| |
Treatment - Local |
|
| |
Surgery
Reconstruction
|
P2-15
P2-16
|
| |
Treatment - Adjuvant |
|
| |
Adjuvant Endocrine Therapy
Adjuvant Therapy - Targeted
Adjuvant Therapy - Other
|
P2-17
P2-18
P2-19
|
| |
|
|
| 7:00 am - 9:00 am |
POSTER DISCUSSION III: Genomics - Ballroom A
7:00 am Viewing
7:45 am Discussion
Discussant: Laura J. van't Veer, PhD
University of California San Francisco
San Francisco, CA |
|
| |
|
|
| 7:00 am - 9:00 am |
POSTER DISCUSSION IV: Survivorship - Ballroom B
7:00 am Viewing
7:45 am Discussion
Discussant: Dawn Hershman, MD, MS
Columbia University Medical Center
New York, NY |
|
| |
|
|
| 9:00 am - 9:30 am |
PLENARY LECTURE 2 – Exhibit Hall D |
|
| |
Macrophages as Novel Targets for Therapy in Breast Cancer
Lisa M. Coussens, PhD
University of California San Francisco
San Francisco, CA |
|
| |
|
|
| 9:30 am - 11:15 am |
GENERAL SESSION 3 – Exhibit Hall D
Moderator: Jose Baselga, MD, PhD, Massachusetts General Hospital, Boston, MA
|
|
| |
|
|
| 9:30 am |
S3-1. Update of International Breast Cancer Study Group trial 23-01 to compare axillary dissection versus no axillary dissection in patients with clinically node negative breast cancer and micrometastases in the sentinel node
Galimberti V, Cole BF, Zurrida S, Viale G, Luini A, Veronesi P, Baratella P, Chifu C, Sargenti M, Intra M, Gentilini O, Massarut S, Garbay J-R, Zgajnar J, Galatius H, Recalcati A, Littlejohn D, Bamert M, Price KN, Goldhirsch A, Gelber RD, Veronesi U. International Breast Cancer Study Group Trial 23-01 Investigators.
|
|
| |
|
|
| 9:45 am |
S3-2. Neoadjuvant chemotherapy adapted by interim response improves overall survival of primary breast cancer patients - results of the GeparTrio trial
von Minckwitz G, Blohmer JU, Costa S, Denkert C, Eidtmann H, Eiermann W, Gerber B, Hanusch C, Hilfrich J, Huober J, Jackisch C, Kaufmann M, Kümmel S, Paepke S, Schneeweiss A, Untch M, Zahm DM, Mehta K, Loibl S. German Breast Group, Neu-Isenburg; St. Gertrauden Krankenhaus, Berlin; Universitäts-Frauenklinik, Magdeburg; Charité, Berlin; Universitäts-Frauenklinik, Kiel; Frauenklinik vom Roten Kreuz, München; Universitäts-Frauenklinik, Rostock; Henrietten-Stiftung, Hannover; Brustzentrum Kantonsspital St. Gallen / Universitäts-Frauenklinik Tübingen; Frauenklinik, Klinikum, Offenbach; Universitäts-Frauenklinik, Frankfurt; Klinikum Essen Mitte, Essen; Universitäts-Frauenklinik Rechts der Isar, München; Universitäts-Frauenklinik, Heidelberg; Frauenklinik, Berlin; Brustzentrum SRH Waldkliniken, Gera.
|
|
| |
|
|
| 10:00 am |
S3-3. Association of PTEN loss and PIK3CA mutations on outcome in HER2+ metastatic breast cancer patients treated with first-line lapatinib plus paclitaxel or paclitaxel alone
Xu B-h, Guan Z-z, Shen Z-z, Tong Z-s, Jiang Z-f, Yang J-I, DeSilvio M, Leigh M, Ellis C. Cancer Hospital, CAMS & PUMC; Sun Yat-Sen Medical University Cancer Center; Shanghai Cancer Center, Fudan University; Tianjin Medical University Cancer Institute and Hospital; Hospital Affiliated to Military Medical Science; Beijing 301 PLA Hospital; GlaxoSmithKline. |
|
| |
|
|
| 10:15 am |
S3-4. ER downregulation with fulvestrant in combination with pan-PI3K inhibitor BKM120 synergizes against ER+/PI3K-mutant breast cancer xenografts in vivo
Miller TW, Fox EM, Balko JM, Meszoely IM, Sanders ME, Kuba MG, Wagle N, Garraway LA, Maira S-M, Arteaga CL. Vanderbilt University, Nashville, TN; Dana-Farber Cancer Institute, Boston, MA; Novartis Inst. for Biomedical Research, Basel, Switzerland. |
|
| |
|
|
| 10:30 am |
S3-5. Next generation sequencing reveals co-activating events in the MAPK and P13K/AKT pathways in metastatic triple negative breast cancers
O'Shaughnessy J, Craig DW, Kiefer J, Sinari S, Moses TM, Wong S, Aldrich J, Christoforides A, Dinh J, Itzatt T, Blum J, Kurdoglu A, Salhia B, Baker A, Siddiqui A, Hoang L, Billings P, Trent JM, Mousses S, Von Hoff D, Carpten JD. Baylor Sammons Cancer Center, Dallas, TX; Translational Genomics Research Institute, Phoenix, AZ; Life Technologies, Carlsbad, CA; US Oncology, The Woodlands, TX. |
|
| |
|
|
| 10:45 am |
S3-6. Neoadjuvant chemotherapy of paclitaxel with or without Rad001: Results of the non-responder part of the GEPARQUINTO study (GBG 44)
Huober J, Hanusch C, Fasching PA, Rezai M, Eidtmann H, Kittel K, Schwedler K, Tesch H, Höß C, Mau C, Khandan F, Krabisch P, Loibl S, Nekljudova V, Untch M, von Minckwitz G. Kantonsspital St. Gallen/Universitäts-Frauenklinik Tübingen; Frauenklinik vom Roten Kreuz, München; Universitäts-Frauenklinik, Erlangen. |
|
| |
|
|
| 11:00 am |
S3-7. Everolimus for postmenopausal women with advanced breast cancer: updated results of the BOLERO-2 phase III trial
Hortobagyi GN, Piccart M, Rugo H, Burris H, Campone M, Noguchi S, Gnant M, Pritchard KI, Vittori L, Mukhopadhyay P, Sahmoud T, Lebwohl D, Baselga J. The University of Texas, MD Anderson Cancer Center, Houston, TX; Jules Bordet Institute (Institut Jules Bordet), Brussels, Belgium; University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, CA; Sarah Cannon Research Institute, Nashville, TN; Institut de Cancérologie de l'Ouest - René Gauducheau, Centre de Recherche en Cancérologie, Nantes Saint Herblain, France ; Osaka University, Department of Breast and Endocrine Surgery, Osaka, Japan; Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Sunnybrook Odette Cancer Centre and the University of Toronto, Toronto, Canada; Novartis Pharma AG, Basel, Switzerland; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA. |
|
| |
|
|
| 11:15 am - 12:00 pm |
William L. McGuire Memorial Lecture – Exhibit Hall D |
|
| |
Translating genomic insights into improved breast cancer management
Joe Gray, PhD
Oregon Health & Science University
Portland, OR
|
|
| |
|
|
| 12:00 pm - 1:35 pm |
LUNCH |
|
| |
|
|
| 12:15 pm - 1:15 pm |
PRODUCT THEATRE - Exhibit Hall C - Exhibit Area
Celgene Product Theatre
Meeting open only to delegates from Europe
|
|
| |
|
|
| 12:30 pm - 1:35 pm |
CASE DISCUSSION 1 – Ballroom A
|
|
| |
Moderator: Mothaffar Rimawi, MD,
Baylor College of Medicine,
Houston, TX |
|
| |
|
|
| |
Panelists:
John Benson, MD
Cambridge University
Cambridge, UNITED KINGDOM
Lisa Carey, MD
University of North Carolina
Chapel Hill, NC
Daniel Hayes, MD
University of Michigan
Ann Arbor, MI
Wendy Woodward, MD
MD Anderson Cancer Center
Houston, TX
Kay Wissmann
IL Deadline Action Network (NBCC)
Carbondale, IL
|
|
| |
|
|
| 12:30 pm - 1:35 pm |
BASIC SCIENCE FORUM - Ballroom B |
|
| |
Estrogen Receptor
Moderator: Suzanne A.W. Fuqua, PhD,
Baylor College of Medicine,
Houston, TX
Steroid receptor cistromics
Myles Brown, MD
Dana-Farber Cancer Institute
Boston, MA
Nuclear receptor coactivators: Physiology and disease
Bert W. O'Malley, MD
Baylor College of Medicine
Houston, TX
|
|
| |
|
|
| 1:45 pm - 3:15 pm |
MINI-SYMPOSIUM 1 - Ballroom B |
|
| |
Tumor Heterogeneity and Metastasis
Moderator: Rachel Schiff, PhD, Baylor College of Medicine, Houston, TX
|
|
| |
|
|
| |
Imaging cancer invasion and experimental therapy response: How to overcome resistance niches
Peter Friedl, MD, PhD
Radboud University Nijmegen
HB Nijmegen, NETHERLANDS
Tumor-entrained neutrophils inhibit breast cancer metastasis seeding in the lung
Robert Benezra, PhD
Memorial Sloan-Kettering Cancer Center
New York, NY
Tumor heterogeneity and metastasis
Matthew J. Ellis, MB, BChir, PhD
Washington University School of Medicine
St. Louis, MO
|
|
| |
|
|
| 1:45 pm - 3:15 pm |
MINI-SYMPOSIUM 2 - Exhibit Hall D |
|
| |
Environmental Exposures, Epigenetics, and Epidemiology
Moderator: Cheryl Lyn Walker, PhD, UT MD Anderson Cancer Center, Houston, TX |
|
| |
|
|
| |
Epidemiology of preeclampsia and other early exposures on breast cancer risk
Michele R. Forman, PhD
UT Austin
Austin, TX
Environ exposures, epigenetics & epidemiology influence of environmental factors on pubertal maturation and breast cancer etiology
Robert A. Hiatt, MD, PhD
University of California, San Francisco
San Francisco, CA
Breast cancer and the environment: Developmental reprogramming of cancer susceptibility by early life environmental exposures
Cheryl Lyn Walker, PhD
UT MD Anderson Cancer Center
Houston, TX
|
|
| |
|
|
| 3:15 pm - 5:15 pm |
GENERAL SESSION 4 – Exhibit Hall D
Moderator: Emiel JT Rutgers, MD, PhD, Netherlands Cancer Institute, Amsterdam, NETHERLANDS
|
|
| |
|
|
| 3:15 pm |
S4-1. Overdiagnosis in breast cancer screening: Methodological considerations of current estimates
Smith RA, Duffy SW. American Cancer Society, Atlanta, GA; Queen Mary University of London, London, United Kingdom.
|
|
| |
|
|
| 3:30 pm |
S4-2. The risk of contralateral breast cancer in BRCA1/2 carriers compared to non-BRCA1/2 carriers in an unselected cohort
van den Broek AJ, Schmidt MK, Tollenaar RAEM, van 't Veer LJ, van Leeuwen FE. Netherlands Cancer Institute, Amsterdam, Netherlands; Leiden University Medical Center, Leiden, Netherlands.
|
|
| |
|
|
| 3:45 pm |
S4-3. Prospective comparison of risk assessment tools in early breast cancer (recurrence score, uPA/PAI-1, central grade, and luminal subtypes): Final correlation analysis from the phase III WSG-Plan B trial
Gluz O, Kreipe H, Degenhardt T, Kates R, Christgen M, Liedtke C, Shak S, Clemens M, Markmann S, Uleer C, Augustin D, Thomssen C, Nitz U, Harbeck N. West German Study Group, Moenchengladbach, Germany; Medizinische Hochschule, Hannover, Germany; University of Muenster, Muenster, Germany; Genomic Health Inc, Redwood City; Klinikum Mutterhaus, Trier, Germany; Klinikum Suedstadt, Rostock, Germany; Gynecology Practice, Hildesheim, Germany; Klinikum Deggendorf, Deggendorf, Germany; University of Halle/Saale, Halle/Saale, Germany; Bethesda Clinics, Moenchengladbach, Germany; University of Cologne, Cologne, Germany.
|
|
| |
|
|
| 4:00 pm |
S4-4. Clarifying the risk of breast cancer in women with atypical breast lesions
Coopey SB, Mazzola E, Buckley JM, Sharko J, Belli AK, Kim EMH, Polufriaginof F, Parmigiani G, Garber JE, Smith BL, Gadd MA, Specht MC, Guidi AJ, Roche CA, Hughes KS. Massachusetts General Hospital, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; Newton-Wellesley Hospital, Newton, MA; Wayne State University, Detroit, MI.
|
|
| |
|
|
| 4:15 pm |
S4-5. Comparison of PAM50 risk of recurrence (ROR) score with oncotypeDx and IHC4 for predicting residual risk of RFS and distant RFS after endocrine therapy: A TransATAC study
Dowsett M, Lopez-Knowles E, Sidhu K, Pineda S, Cowens JW, Ferree S, Storhoff J, Schaper C, Cuzick J. Royal Marsden Hospital and Breakthrough Breast Cancer Centre, London, United Kingdom; Wolfson Institute of Preventive Medicine, London, United Kingdom; Nanostring Technologies, Seattle, WA.
|
|
| |
|
|
| 4:30 pm |
S4-6. A quantitative multigene RT-PCR assay for predicting recurrence risk after surgical excision alone without irradiation for ductal carcinoma in situ (DCIS): A prospective validation study of the DCIS score from ECOG E5194
Solin LJ, Gray R, Baehner FL, Butler S, Badve S, Yoshizawa C, Shak S, Hughes L, Sledge G, Davidson N, Perez EA, Ingle J, Sparano JA, Wood W.
Albert Einstein Medical Center, Philadelphia, PA; Eastern Cooperative Oncology Group, Boston, MA; Genomic Health, Inc., Redwood City, CA; Indiana University, Indianapolis, IN; The Hope Center, Cartersville, GA; University of Pittsburgh, Pittsburgh, PA; Mayo Clinic Jacksonville, Jacksonville, FL; Mayo Clinic Rochester, Rochester, MN; Albert Einstein College of Medicine, Bronx, NY; Emory University, Atlanta, GA.
|
|
| |
|
|
| 4:45 pm |
S4-7. Results of a randomized, double-blind, multicenter, placebo-controlled study of adjuvant lapatinib in women with early-stage ErbB2-overexpressing breast cancer
Goss P, Smith I, O’Shaugnessy J, Ejlertsen B, Kaufmann M, Boyle F, Buzdar A, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard K, Aktan G, Rappold E, Williams L, Finkelstein D.
Massachusetts Gen Hosp, Boston MA; Royal Marsden Hosp, London, UK; Baylor Sammons Cancer Ctr, Dallas TX; Rigshospitalet, Copenhagen, Denmark; JW Goethe-Universität, Frankfurt, Germany; Royal North Shore Hosp, Sydney, Australia; UT MD Anderson Cancer Ctr, Houston TX; Centre GF Leclerc, Dijon, France; Northwestern Univ, Chicago IL; Hosp Universitario San Carlos, Madrid, Spain; Jules Bordet Inst, Brussels, Belgium; Toronto-Sunnybrook Regional Cancer Ctr, Toronto, Ontario; GlaxoSmithKline, Collegeville PA and Uxbridge, UK. |
|
| |
|
|
| 5:00 pm |
S4-8. First results of AVEREL, a randomized phase III trial to evaluate bevacizumab (BEV) in combination with trastuzumab (H) + docetaxel (DOC) as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC)
Gianni L, Romieu G, Lichinitser M, Serrano S, Mansutti M, Pivot X, Smirnova I, Moliterni A, Andre F, Chan A, Lipatov O, Chan S, Wardley W, Greil R, Provencher L, Moore N, Prot S, Semiglazov V.
Osp San Raffaele, Milan, Italy; Ctr Régionale de Lutte contre le Cancer, Montpellier, France; NN Blokhin Oncol Res Ctr, Moscow, Russian Federation; Fundação Pio XII Hosp de Cancer, Barretos, Brazil; Univ Hosp, Udine, Italy; Univ Hosp Jean Minjoz, Besançon, France; Med Rad Sci Ctr, Obinsk, Russian Federation; Istituto Nazionale Tumori, Milan, Italy; Inst Gustave Roussy, Villejuif, France; Mount Hosp, Perth, Australia; Republican Clin Oncol Dispensary, Ufa, Russian Federation; Nottingham Univ Hospitals, Nottingham, UK; The Christie, Manchester, UK; III. Med Universitätsklinik, Salzburg, Austria; CHA-Hôpital du Saint-Sacrement, Québec, Canada; F Hoffman-LaRoche, Basel, Switzerland; NN Petrov Res Inst of Oncol, St Petersburg, Russian Federation. |
|
| |
|
|
| 5:15 pm - 7:00 pm |
POSTER SESSION 3 & RECEPTION – Exhibit Halls A-B |
|
| |
|
|
| |
Tumor Cell Biology
Novel/Emerging Therapeutic Targets
New Agents and Mechanisms
Micro RNAs
Molecular Profiles
Tumor Heterogeneity/Molecular Subclassification
Genomics
|
P3-01
P3-02
P3-03
P3-04
P3-05
P3-06 |
| |
|
|
| |
Detection and Diagnosis
Axillary Staging and Sentinel Nodes
|
P3-07 |
| |
|
|
| |
Epidemiology, Risk, and Prevention
Prevention - Behavioral Interventions
Prevention - Nutritional Studies
Prevention - Preclinical Studies and Model Systems
Prevention - Clinical Trials
|
P3-08
P3-09
P3-10
P3-11
|
| |
|
|
| |
Treatment - Local
Breast Conservation
Radiotherapy
|
P3-12
P3-13
|
| |
|
|
| |
Treatment - Therapeutic Strategies
Neoadjuvant Chemotherapy
Neoadjuvant Endocrine Therapy
New Drugs and Treatment Strategies
Novel Drugs and Targeted Agents
Signal Transduction Inhibitors
|
P3-14
P3-15
P3-16
P3-17
P3-18 |
| |
|
|
| 5:15 pm - 7:00 pm |
POSTER DISCUSSION V: HER2 – Ballroom A
5:15 pm Viewing
5:30 pm Discussion
|
|
| |
Discussant: Michael F. Press, MD, PhD
USC/ Norris Comprehensive Cancer Center
Los Angeles, CA |
|
| |
|
|
| 5:15pm - 7:00 pm |
POSTER DISCUSSION VI: Cost Effectiveness/Utilization – Ballroom B
5:15 pm Viewing
5:30 pm Discussion
|
|
| |
Discussant:Thomas J. Smith, MD, FACP
Johns Hopkins
Baltimore, MD |
|
| |
|
|
| 5:15 pm - 7:00 pm |
POSTER SESSION ONGOING TRIALS 2 - Exhibit Hall B |
|
| |
|
|
| |
Chemotherapy
Endocrine Therapy
Diagnosis and Biomarkers
Prevention
Imaging
Radiotherapy
Side-effect Control
|
OT2-01
OT2-02
OT2-03
OT2-04
OT2-05
OT2-06
OT2-07 |
| |
|
|
| 7:30 pm - 9:30 pm |
OPEN SATELLITE EVENT - Marriott Rivercenter, Grand Ballroom
Targeting breast Cancer Molecular Phenotypes: A Dialogue Between Community and Academic Oncologists
WEBSITE: http://primeoncology.org/sanantoniosymposium2011 |
|
| |
|
|
|
| |
|
Tuesday
|
Wednesday
|
Friday
|
Saturday
|
| |
|
|
